Literature DB >> 36074783

The characteristics of bacteremia among patients with acute febrile illness requiring hospitalization in Indonesia.

Pratiwi Soedarmono1, Aly Diana2,3, Patricia Tauran4, Dewi Lokida5, Abu Tholib Aman6, Bachti Alisjahbana7, Dona Arlinda8, Emiliana Tjitra8, Herman Kosasih2, Ketut Tuti Parwati Merati9, Mansyur Arif4, Muhammad Hussein Gasem10, Nugroho Harry Susanto2, Nurhayati Lukman2, Retna Indah Sugiyono2, Usman Hadi11, Vivi Lisdawati12, Karine G Fouth Tchos13, Aaron Neal13, Muhammad Karyana2,8.   

Abstract

Blood culturing remains the "gold standard" for bloodstream infection (BSI) diagnosis, but the method is inaccessible to many developing countries due to high costs and insufficient resources. To better understand the utility of blood cultures among patients in Indonesia, a country where blood cultures are not routinely performed, we evaluated data from a previous cohort study that included blood cultures for all participants. An acute febrile illness study was conducted from July 2013 to June 2016 at eight major hospitals in seven provincial capitals in Indonesia. All participants presented with a fever, and two-sided aerobic blood cultures were performed within 48 hours of hospital admission. Positive cultures were further assessed for antimicrobial resistance (AMR) patterns. Specimens from participants with negative culture results were screened by advanced molecular and serological methods for evidence of causal pathogens. Blood cultures were performed for 1,459 of 1,464 participants, and the 70.6% (1,030) participants that were negative by dengue NS1 antigen test were included in further analysis. Bacteremia was observed in 8.9% (92) participants, with the most frequent pathogens being Salmonella enterica serovar Typhi (41) and Paratyphi A (10), Escherichia coli (14), and Staphylococcus aureus (10). Two S. Paratyphi A cases had evidence of AMR, and several E. coli cases were multidrug resistant (42.9%, 6/14) or monoresistant (14.3%, 2/14). Culture contamination was observed in 3.6% (37) cases. Molecular and serological assays identified etiological agents in participants having negative cultures, with 23.1% to 90% of cases being missed by blood cultures. Blood cultures are a valuable diagnostic tool for hospitalized patients presenting with fever. In Indonesia, pre-screening patients for the most common viral infections, such as dengue, influenza, and chikungunya viruses, would maximize the benefit to the patient while also conserving resources. Blood cultures should also be supplemented with advanced laboratory tests when available.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36074783      PMCID: PMC9455855          DOI: 10.1371/journal.pone.0273414

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


Introduction

Bloodstream infections (BSI) [1] are a significant cause of morbidity and mortality in both developing and developed countries [2-4]. The “gold standard” method for BSI diagnosis remains blood culturing [5-7], a straightforward laboratory technique that is inaccessible to many developing countries due to high costs and insufficient resources. Blood cultures provide both definitive microbiological evidence of infection and serve as a crucial tool to monitor the serious global health threat of antimicrobial resistance (AMR) [8]. The threat of AMR further exacerbates the burden felt in countries without routine access to this diagnostic method, including in Indonesia, and allows AMR to continue threatening populations worldwide. The early and accurate identification of causative microorganisms and their susceptibility to antibiotics is essential to improve patient survival and prevent emerging AMR pathogens. Even with access to routine blood cultures, the interpretation of results can be challenging and should align with clinical observations. Bacterial growth is a consequence of the initial quantity of bacteria in the specimen, the quality of the specimen, the timing of specimen collection with clinical treatment, and the biological nature of the bacteria. Negative blood cultures alone are not definitive for diagnosis, as advanced laboratory methods often detect missed culturable organisms from the same specimen types [9, 10]. Routine analysis of specimens can be impacted by contamination from the environment of the patient [11, 12]. In most settings, only 5 to 13% of blood cultures will become positive, and of those, 20–56% result from contamination [7, 13–16]. In Indonesia, acute febrile illness resulting from BSIs remains a common cause of hospitalization, morbidity, and mortality. Although infectious diseases are the primary cause of hospitalization in the country, clinicians do not routinely perform blood cultures as part of standard clinical care [17]. When clinicians perform blood cultures, generally in severely ill patients referred to tertiary care, they do not consistently use best laboratory practices [18]. Data on blood culture use, performance, and contamination rates in Indonesia remain very limited [17, 19, 20]. Consequently, data on the emergence and spread of AMR pathogens in the country is unreliable and incomplete, complicating antibiotic stewardship efforts in the region. The epidemiology of pathogens associated with fever in Indonesia is not well understood, as public health surveillance data is limited and only a few local studies have been conducted [19, 21–26]. Among published studies, dengue virus, chikungunya virus, influenza virus, Salmonella enterica serovar Typhi, Rickettsia spp., and Leptospira spp. are consistently the most common causes of acute febrile illness hospitalizations. A study in Papua from November 1997 to February 2000 enrolled 226 hospitalized patients that were negative for malaria, the majority of whom were determined to have typhoid fever (18%), leptospirosis (12%), rickettsioses (8%), and dengue fever (7%) [23]. An observational fever study in Bandung identified dengue virus in 12.4% of fever episodes, followed by S. Typhi (7.4%), and chikungunya virus (7.1%) [24, 26, 27]. A 2005–2006 study in Semarang found rickettsioses and leptospirosis in 7% and 10%, respectively, of 137 acute undifferentiated fever cases [21]. The parent study of the research presented here found the most prevalent pathogens among participants at eight hospitals in 7 major cities in Indonesia to be dengue virus (27–52%), Rickettsia spp. (2–12%), S. Typhi (0.9–13%), influenza virus (2–6%), Leptospira spp. (0–5%), and chikungunya virus (0–4%) [19]. To better understand the utility of blood cultures among patients with acute febrile illness in Indonesia, we evaluated data from a previously published multicenter observational prospective cohort study conducted across the country [19]. Gaining insight into pathogens commonly identified by blood culture, contamination rates, AMR patterns, and disease outcomes will provide actionable evidence to support decision making for Indonesia’s national blood culture testing policy.

Methods

Study design and sample collection

A prospective observational study enrolling febrile patients who required hospitalization was conducted by the Indonesia Research Partnership on Infectious Disease (INA-RESPOND) from July 2013 to June 2016 at eight major hospitals in seven provincial capitals in Indonesia: Dr. Cipto Mangunkusumo Hospital in Jakarta, Sulianti Saroso Infectious Disease Hospital in Jakarta, Dr. Wahidin Sudirohusodo Hospital in Makassar, Dr. Sardjito Hospital in Yogyakarta, Dr. Hasan Sadikin Hospital in Bandung, Sanglah General Hospital in Denpasar, Dr. Soetomo Hospital in Surabaya, and Dr. Kariadi Hospital, in Semarang. The full details of this study, known as AFIRE, were published previously [19]. Briefly, inclusion criteria consisted of axillary body temperature ≥38˚C, ≥1 year of age, and hospitalization within the past 24 hours. Patients were excluded from the study if they had subjective fever for ≥14 days or were hospitalized in the last 3 months. Demographic, clinical, and laboratory data, including hematology results, were collected at baseline, once during days 14–28, and three months after enrollment. Blood and other biological specimens were collected at each study visit. During the baseline visit, blood was collected for cultures, clinically relevant rapid diagnostic tests when available, and dengue virus rapid diagnostic tests. Dengue virus infection remains a significant burden across Indonesia [28, 29], with disease incidence increasing in recent years [30]. Though other viral agents are present in Indonesia, none are as prevalent as dengue virus [24, 31], and most are challenging to diagnose due to limitations with available rapid diagnostic tests [32, 33]. Given the widespread prevalence of dengue virus infection, and the very high specificity (almost 100%) and good sensitivity (70–87%) of NS1 antigen rapid diagnostic tests [34], we employed universal dengue virus screening to rapidly resolve the unknown etiologies of study participants. Participants with negative NS1 antigen tests were further considered for BSIs through blood culture tests and other etiologies, as determined through advanced testing at the INA-RESPOND reference laboratory.

Laboratory tests

Aerobic blood cultures were performed within 48 hours of a participant being admitted to the emergency department of a study site. Blood volumes of approximately 5–8 mL for adults and 1–3 mL for pediatrics were collected from each arm, whenever possible, directly into separate aerobic blood culture bottles. If blood could not be collected from each arm due to clinical reasons, blood was collected from a single arm for a single aerobic blood culture bottle. Study physicians were advised to delay the administration of IV antibiotics until blood specimens were collected, provided that there were no immediate risks to the participant. Each hospital performed a complete blood count (CBC) as part of standard-of-care procedures during enrollment. Inoculated aerobic blood culture bottles were incubated using a continuous-monitoring blood culture system, either BACTEC (Becton-Dickinson, Sparks, Maryland) or BacT/Alert (bioMérieux, Inc., Durham, North Carolina) [35]. Manufacturer guidelines were followed for all bacterial cultures, and automated growth identification systems, either BD Phoenix (Becton Dickinson) or VITEK 2 (bioMérieux, Inc., Durham, North Carolina), were used for bacterial identification and antibiotic susceptibility testing. Blood cultures were performed and analyzed at the hospitals’ nationally accredited clinical laboratories by trained, certified staff. All instruments and standards were calibrated appropriately according to manufacturer guidelines, and all tests were run alongside appropriate positive and negative control to ensure the integrity and accuracy of the results. Organism identification was considered acceptable when the confidence level in the automated growth identification system was ≥95% probability [36]. Quality control tests were performed weekly at all site laboratories, and each new lot of ID cards was tested using validated stocks of culture organisms. Growth observed in blood cultures was classified as either “true positive” or “false positive.” True positives included pathogenic bacterial species, particularly those identified as priority pathogens by the World Health Organization Global Antimicrobial Resistance and Use Surveillance System (WHO GLASS) [37], observed in at least one blood culture. Additionally, non-WHO GLASS pathogens found in either one or both cultures and being consistent with clinical manifestations were also considered to be true positives. False positives included growth of bacteria and fungi which were not clinically relevant and growth of known culture contaminants. Bacterial culture contamination was defined as any culture growing viridans group streptococci, Corynebacterium spp., Bacillus spp., Diphtheroid spp., Micrococcus spp., Propionibacterium spp., and coagulase-negative staphylococci [12]. At the INA-RESPOND reference laboratory, specimens from all participants were screened for dengue using NS1 antigen ELISA, dengue RT-PCR, and dengue IgM and IgG. Molecular tests in acute specimens and serological tests in acute and convalescent specimens were performed to detect bacterial infections such as S. Typhi, S. Paratyphi A, Leptospira spp., and Rickettsia typhi, and viruses such as influenza, chikungunya, and measles. Details of diagnostic assays for this study were previously described [19].

Statistical analysis

Data were collected in OpenClinica (OpenClinica LLC, MA, USA) and analyzed using STATA v.15.1 (StataCorp LLC, TX, USA). Proportions were compared between categorical variables using Pearson’s chi-squared test. The student’s t-test was used to assess continuous variables. All p-values were two-sided with a significance level set to p<0.05.

Ethical clearance

Ethical approvals for the AFIRE study were granted by the Institutional Review Boards of the National Institute of Health Research and Development (NIHRD), Indonesia Ministry of Health (KE.01.05/EC/407/2012, dated 23 May 2012), the Faculty of Medicine at the University of Indonesia and RSUPN Dr. Cipto Mangunkusumo Hospital (451/PT02.FK/ETIK/2012, dated 23 July 2012), and RSUD Dr. Soetomo Hospital (192/Panke.KKE/VIII/2012, dated 13 August 2012). All eligible patients who agreed to participate in the study provided written informed consent before enrollment.

Results

A total of 1,464 participants were enrolled in the AFIRE study, and aerobic blood cultures were performed for 1,459 participants (Fig 1). The remaining 5 participants had insufficient blood specimens for following reasons: 1 adult was in a severe condition (decreased of consciousness), 2 participants (1 child and 1 adult) self-discharged against medical advice, and the guardians of 2 children refused to allow more blood to be drawn. Bacterial growth was observed for 10.3% (150) participants, including 56.0% (84) with WHO GLASS pathogens, 5.3% (8) with other non-WHO GLASS pathogens, and 38.7% (58) with false positives. No growth was observed for 89.7% (1,309) participants. All participants were screened for dengue virus by NS1 antigen and dengue IgM/IgG antibody tests, resulting in 29.4% (429) positive results, 415 from “No Growth” and 14 from the “False Positive” group. The remaining 70.6% (1,030) dengue-negative participants were included in this analysis.
Fig 1

General blood culture results observed among study participants.

Participants provided blood from either one or both arms for aerobic blood cultures, and bacterial growth was observed from either one or both sides. All participants providing blood underwent screening for dengue virus infection by NS1 antigen test.

General blood culture results observed among study participants.

Participants provided blood from either one or both arms for aerobic blood cultures, and bacterial growth was observed from either one or both sides. All participants providing blood underwent screening for dengue virus infection by NS1 antigen test.

Results of blood cultures: Community-Acquired Infection (CAI)

Bacteremia was observed in 8.9% (92) of the 1,030 dengue-negative participants, with the most frequent pathogens being S. Typhi in 41 and S. Paratyphi A in 10 participants, Escherichia coli in 14 participants, and Staphylococcus aureus in 10 participants (Table 1). Dengue-negative false positive results were observed in 4.3% (44) participants, with the most frequent microorganism being contaminating coagulase-negative Staphylococcus spp. in 32 participants. From the 136 dengue-negative participants with any microbial growth, 97.8% (133) had blood collected from two sides of the body (Fig 1). Growth from both sides was observed in 58.7% of participants with true positive results and 25.0% of participants with false positive results.
Table 1

Specific blood culture results among dengue-negative study participants.

PathogenPositive ResultsPercent of Positive Results Within Group
WHO GLASS Priority Pathogens (N = 84)Salmonella spp.Salmonella enterica serovar Typhi (41)S. Paratyphi A (10)5160.7
Escherichia coli 1416.7
Staphylococcus aureus 1011.9
Klebsiella pneumoniae 56.0
Acinetobacter spp.22.4
Streptococcus pneumoniae 22.4
Non-WHO GLASS Pathogens (N = 8) Pseudomonas aeruginosa 225.0
Staphylococcus hominis ssp. hominis112.5
Enterobacter aerogenes 112.5
Enterococcus faecalis 112.5
Pseudomonas cepacea 112.5
Pseudomonas spp.112.5
Streptococcus pyogenes 112.5
Clinically Irrelevant Growth (N = 7)Pantoea spp.228.6
Sphingomonas paucimobilis 228.6
Alcaligenes faecalis 114.3
Candida pelliculosa 114.3
Rhizobium radiobacter 114.3
Contaminants (N = 37) Coagulase-Negative Staphylococcus 3286.5
Bacillus spp.25.4
Micrococcus luteus 12.7
Kocuria spp.12.7
Streptococcus viridans 12.7
No Growth (N = 894) None 00.0
Since S. Typhi and S. Paratyphi A were found in over half (55.4%) of true positives (Table 1), participants with true positive results were analyzed in either Salmonella spp. or non-Salmonella spp. groups (Table 2). Participant demographics revealed nearly equal numbers of male and female participants in the study, with equal numbers of true positive cases in the two groups. Participants in the Salmonella spp. group were significantly younger, with a median age of 14 years old, compared to non-Salmonella spp. and false positive groups, with median ages of 44 years old and 24.6 years old, respectively. Over 62.7% of Salmonella spp. cases were in participants ≤18 years old, while only 26.8% of non-Salmonella spp. cases were in this same age range. There were no significant differences between all groups in the days of onset before hospitalization or the length of hospitalization.
Table 2

Participant characteristics, hematology results, and mortality.

 True Positive (92)False Positive and No Growth (938)Total (1,030)
Salmonella spp. (51)Non-Salmonella spp. (41)
Male, N (%)29 (56.9)17 (41.5)502 (53.9)553 (53.7)
Median age, years (range, IQR)14 (2.5–54, 14.7)44 (1–84, 40.0)24.6 (1–92, 36.5)24 (1–92, 36.2)
Mean age, years (SD)16.2 (11.1)D,E39.6 (24.0)D,F28.6 (21.4)E,F28.5 (21.4)
Distribution of cases by age group, N (%)  
1–5 years4 (7.8)5 (12.2)154 (16.4)163 (15.8)
>5–18 years28 (54.9)D,E6 (14.6)D184 (19.6)E218 (21.2)
>18–45 years18 (35.3)11 (26.8)365 (38.9)394 (38.3)
>45–65 years1 (2.0)D,E13 (31.7)C,D179 (19.1)C,E193 (18.7)
>65 years0 (0.0)B,D6 (14.6)C,D56 (6.0)B,C62 (6.0)
Days of onset before hospitalization, median (range, IQR)7 (1–13, 4)4 (1–15, 4)4 (1–15, 4)4 (1–15, 4)
Length of hospitalization, median (range, IQR)7 (2–38, 4)8 (2–40, 7)6 (1–55, 3.3)6 (1–55, 4)
Received intravenous antibiotics prior to blood collection, N (%)9 (17.6)A,E16 (39.0)A389 (41.5)E414 (40.2)
Received any antibiotics following blood collection, N (%)31/31 (100)E18/18 (100)A,C199/269 (74.0)A,C,E248/318 (77.9)
Hematology at enrollment, N (%)  
Leukopenia13/51 (25.5)E5/41 (12.2)120/937 (12.8)E138/1029 (13.4)
Normal Leukocyte35/51 (68.6)A,E19/41 (46.3)A462/937 (49.3)E516/1029 (50.1)
Leukocytosis3/51 (5.9)D,E17/41 (41.5)D355/937 (37.9)E375/1029 (36.4)
Lymphopenia16/44 (36.4)B,D26/38 (68.4)D442/810 (54.6)B484/892 (54.3)
Normal Lymphocyte17/44 (38.6)A7/38 (18.4)A,C285/810 (35.2)C309/892 (34.6)
Lymphocytosis11/44 (25.0)E5/38 (13.2)83/810 (10.2)E99/892 (11.1)
Outcome, N (%)  
Died3 (5.9)D11 (26.8)D,F69 (7.4)F83 (8.1)

Study participants with true positive culture results were sub-categorized into Salmonella spp. (consisted of Salmonella enterica serovar Typhi and Paratyphi A) and non-Salmonella spp. groups to better resolve analyses. Comparisons for significance occur across column groups only.

A,B,C indicates p-value <0.05

D,E,F indicates p-value <0.01

Study participants with true positive culture results were sub-categorized into Salmonella spp. (consisted of Salmonella enterica serovar Typhi and Paratyphi A) and non-Salmonella spp. groups to better resolve analyses. Comparisons for significance occur across column groups only. A,B,C indicates p-value <0.05 D,E,F indicates p-value <0.01 Intravenous antibiotics were administered prior to blood collection significantly less frequently in the Salmonella spp. group (17.6%, 9/51) compared to other groups (Table 2). All participants with true positive results were administered antibiotics following blood collection, and 74% of participants with false positive results received antibiotics. Hematology profiles at enrollment differed significantly between the Salmonella spp. and non-Salmonella spp. groups. Leukopenia and normal leukocyte counts were observed in 94.1% (48) of Salmonella spp. cases compared to 58.5% (24) of non-Salmonella spp. cases and 62.0% (582) of false positive and no growth cases. Similarly, leukocytosis was significantly lower in the Salmonella spp. group compared to the other groups. Lymphopenia was observed in 36.4% (16) of the Salmonella spp. cases, which is significantly lower than the 68.4% (26) non-Salmonella spp. cases and the 54.6% (442) false positive and no growth cases. Mortality was significantly higher in the non-Salmonella spp. group compared to the other groups. Cases of true positives were distributed across age groups and study sites (Table 3). While Salmonella spp. were most frequently found in pediatrics (62.7% of cases), E. coli, S. aureus, and K. pneumoniae were most frequently found in adults (85.7%, 80.0%, and 80.0% of cases, respectively). Most Salmonella spp. cases were seen in Bandung (BDG, 41.2%), Semarang (SMG, 23.5%), and Surabaya (SUB, 21.6%). This differed significantly from cases seen in Makassar (MKS, 9.8%), Yogyakarta (YOG, 2.0%), Denpasar (DPS, 2.0%), and Jakarta (JKT, 0.0%). Other than Salmonella spp., there were no significant differences in the distribution of pathogens across study sites, likely due to the low numbers of cases.
Table 3

Positive blood culture pathogens by participant age group and study location.

Pathogen IdentifiedAge group (years old)LocationTotal
≥1–5>5–18>18–45>45–65>65BdgSbySmrDpsMksYogJkt
Salmonella spp.428 (1)18 (1)1 (1)0211112151051
Escherichia coli 113 (1)5 (1)4330403114
Staphylococcus aureus 024 (1)4 (1)0113210210
Klebsiella pneumoniae 0103 (2)101022005
Acinetobacter spp.0110000010012
Enterobacter aerogenes 001 (1)0000010001
Enterococcus faecalis 1000000000011
Pseudomonas aeruginosa 101 (1)0000000202
Pseudomonas cepacea 0000110000001
Pseudomonas species 0010001000001
Streptococcus pneumoniae 1 (1)1 (1)00010001002
Streptococcus pyogenes 0001000010001
Staphylococcus hominis ssp hominis 1 (1)000000000101
Total 9 (2)34 (2)29 (5)14 (5)62717151297592

† Indicates study participants who died

Bdg: Bandung; Sby: Surabaya; Smr: Semarang; Dps: Denpasar; Mks: Makassar; Yog: Yogyakarta; Jkt: Jakarta

† Indicates study participants who died Bdg: Bandung; Sby: Surabaya; Smr: Semarang; Dps: Denpasar; Mks: Makassar; Yog: Yogyakarta; Jkt: Jakarta The 938 participants in the false positive and no growth groups had specimens screened by other laboratory methods to determine potential etiologies (Table 4). PCR on blood specimens identified etiologies in 168 participants, serology identified etiologies in 220 participants, and other methods identified etiologies in 94 participants. Among the culturable bacterial pathogens identified in these groups were the WHO GLASS pathogens S. Typhi (41) and S. Paratyphi A (10), S. pneumoniae (18), K. pneumoniae (8), A. baumanii (7), E. coli (7), and S. aureus (3). When combined with the culture results from the WHO GLASS priority pathogens group in Table 1, 50% of S. Typhi and S. Paratyphi A cases, 33.3% of E. coli cases, 23.1% of S. aureus cases, 61.5% of K. pneumoniae cases, 77.8% of Acinetobacter spp. cases, and 90% of S. pneumoniae cases in the AFIRE study [19] were not identified by blood cultures.
Table 4

Pathogens detected by molecular, serological, or other laboratory methods from participants with false positive and no growth blood cultures.

False Positive and No Growth (N = 938)Confirmatory Methods
PathogenNBlood PCRSerologyOther Methods
Rickettsia typhi 1016536 
Influenza660597: Sputum PCR
Salmonella enterica serovar Typhi and Paratyphi A51348 
Leptospira spp.443113 
Chikungunya38308 
Dengue35035 
Mycobacterium tuberculosis 200020: Sputum Microscopy
Streptococcus pneumoniae 181008: Sputum PCR
Measles1495 
Amoeba110011: Feces Microscopy
RSV11092: Swab PCR
HHV-6990 
Klebsiella pneumoniae 8105: Sputum Culture2: Swab Culture
Acinetobacter baumanii 7104: Sputum PCR1: Swab PCR1: Urine PCR
Escherichia coli 7104: Urine Culture2: Pus Culture
Hepatitis A606 
Pseudomonas aeruginosa 6004: Sputum Culture2: Urine Culture
Enterococcus faecalis 3002: Pus Culture1: Urine Culture
Staphylococcus aureus 3003: Pus Culture
Mycobacterium leprae 2002: Skin Microscopy
Plasmodium spp.2002: Rapid Antigen Test
Seoul virus220 
Adenovirus110 
Ascaris lumbricoides 1001: Feces Microscopy
Ascaris lumbricoides and Trichuris Trichiura1001: Feces Microscopy
Bordetella pertussis and Streptococcus pneumoniae1001: Sputum PCR
HCoV-OC43110 
Enterobacter aerogenes 1001: Sputum Culture
Enterobacter cloacae 1001: Sputum Culture and PCR
Enterococcus avium 1001: Pus Culture
Enterovirus110 
EPEC1001: Feces Culture
HIV110 
Metapneumovirus1001: Swab PCR
Moraxella catarrhalis and Influenza B1001: Sputum Culture and PCR
Mycoplasma pneumoniae 1001: Sputum PCR
Norovirus II110 
Rickettsia felis 110 
Rubella101 
Streptococcus faecalis 1001: Urine Culture
Unknown45600 
Total 938 168 220 94

Plasma, serum, and clinically relevant specimens were collected from all study participants and tested in a central lab for culturable and non-culturable pathogens based on a standard study algorithm and clinical suspicion.

Plasma, serum, and clinically relevant specimens were collected from all study participants and tested in a central lab for culturable and non-culturable pathogens based on a standard study algorithm and clinical suspicion.

Antimicrobial resistance patterns

Antimicrobial resistance patterns were observed in several participants with blood cultures positive for WHO GLASS priority pathogens (Fig 2). Among the 10 S. Paratyphi A cases, evidence of multidrug resistance was observed in one participant and monoresistance in one participant. In contrast, E. coli cases were mostly multidrug resistant (42.9%, 6/14) or monoresistant (14.3%, 2/14), with observed resistances to ampicillin (87.5%, 7/8), co-trimoxazole (60.0%, 3/5), ceftriaxone (45.4%, 5/11), ceftazidime (41.6%, 5/12), cefotaxime (37.5%, 3/8), cefepime (33.3%, 2/6), ciprofloxacin (30.0%, 3/10), and levofloxacin (25.0%, 2/8). Two participants (JOG-A and DPS-A) receiving ceftriaxone died before their antimicrobial resistance test results, and one participant (JOG-B) survived when switched from ceftazidime to ciprofloxacin based on their test results.
Fig 2

Antimicrobial resistance patterns observed in WHO GLASS priority pathogens from true positive blood cultures.

Participants with resistant (R) infections are identified by study location, and participants with sensitive (S) infections or infections with no testing data (ND) are grouped into Other or No Data categories.

Antimicrobial resistance patterns observed in WHO GLASS priority pathogens from true positive blood cultures.

Participants with resistant (R) infections are identified by study location, and participants with sensitive (S) infections or infections with no testing data (ND) are grouped into Other or No Data categories. Methicillin-resistant S. aureus (MRSA) was observed in one participant based on oxacillin susceptibility testing, and two participants with oxacillin-sensitive S. aureus infections died. Both participants with S. pneumoniae bacteremia died, though antimicrobial resistance was only observed in one of the participants. All cases of Acinetobacter spp. and K. pneumoniae that underwent drug sensitivity testing were sensitive to antibiotics.

Disease outcomes

Characteristics and laboratory findings of participants who died during hospitalization are shown in Table 5. A total of 83 participants in this analysis died during hospitalization. Among these, 16.9% (14) had true positive blood cultures (Table 5A), resulting in 15.2% mortality in the true positive group. This mortality rate is twofold higher than the 7.4% mortality observed in the false positive and no growth groups. Overall mortality in the S. Typhi. group (5.9%) was significantly lower than the non-Salmonella spp. group (26.8%). Among deceased participants, there were no significant differences in demographics between the true positive group and false positive and no growth groups. Most deceased participants had comorbidities including diabetes mellitus (4), hepatitis B (3), HIV (2), tuberculosis (2), brain tumor (1), TRALI (1), neoplasia (1), and others (6) (Table 5B). Antimicrobial-resistant pathogens were identified in 3 of the 14 deceased participants with true positives (Table 5). In the false positive and no growth groups, other laboratory methods such as PCR and/or serology were used to identify culturable bacterial pathogens including S. Typhi (2), A. baumanii (1), E. avium (1), E. coli (1), M. catarrhalis (1), and S. pneumoniae (1) (Table 5B).
Table 5

Participant characteristics, clinical diagnoses, and identified pathogens from fatal cases in the study.

(A) Characteristics of deceased participants categorized by blood culture growth result.
True Positive (14) False Positive and No Growth (69) Total (83)
Salmonella enterica serovar Typhi (3) Non-Salmonella spp. (11)
Male, N (%)3 (100)7 (63.6)36 (52.2)46 (55.4)
Distribution of cases by age group, N (%)    
1–5 years0 (0.0)2 (18.2)4 (5.8)6 (7.2)
>5–18 years1 (33.3)1 (9.1)7 (10.1)9 (10.8)
>18–45 years1 (33.3)4 (36.4)24 (34.8)29 (34.9)
>45–65 years1 (33.3)4 (36.4)25 (36.2)30 (36.1)
>65 years0 (0.0)0 (0.0)9 (13)9 (10.8)
Received intravenous antibiotics prior to blood collection, N (%)1 (33.3) 1 (9.1) 34 (49.3) 36 (43.4)
Length of hospitalization, median (range, IQR)4 (2–38) 12 (2–17) 8 (2–54) 8 (2–54)
Comorbidities, N (%)2 (66.6)10 (90.9)60 (86.9)72 (86.7)
(B) Pathogens from fatal cases confirmed by blood culture or other lab methods and the accompanying clinical diagnoses, participant comorbidities, and AMR observations
True Positive (14) Clinical Diagnosis at Death Comorbidities Antimicrobial Resistance
Salmonella enterica serovar Typhi (3)Typhoid feverHepatitis B, HIV, TBNone
Acute limb ischemiaAcute Limb IschemiaNone
Sepsis, typhoid feverTransfusion-Related Acute Lung Injury (TRALI)None
Escherichia coli (2)CholangitisDiabetes, Hepatitis BYes
SepsisAnemiaYes
Klebsiella pneumoniae (2)UTI, diabetic ketoacidosisDiabetesNone
UTIStrokeNone
Staphylococcus aureus (2)UTIDiabetesNone
SepsisDiabetes, Chronic Kidney DiseaseNone
Streptococcus pneumoniae (2)Aseptic meningitis, acute otitis mediaEpilepsyYes
 Myelodysplasia, Hepatitis B (Cirrhosis)None
Pseudomonas aeruginosa (1)Stevens-Johnson syndromeHIV, TB, ToxoplasmosisNo data
Enterobacter aerogenes (1)Cholangitis, SepsisNoneNo data
Staphylococcus hominis ssp hominis (1) CraniopharyngiomaNone
False Positive and No Growth (69) [Confirmatory Methods] Clinical Diagnosis at Death
Mycobacterium tuberculosis (8) [GeneXpert (2), Microscopy (6)]Pulmonary TB (3), Colitis TB and Spondylitis TB, Millar TB, HIV, Community-acquired Pneumonia, Sepsis
Rickettsia typhi (6) [PCR (6)]Sepsis (3), Community-acquired Pneumonia, Meningoencephalitis, Diabetic Neuropathy
Influenza (3) [PCR (2), Serology (1)]Bronchiectasis, Community-acquired Pneumonia, Sepsis
Salmonella Typhi (2) [Serology (2)]Hirschsprung’s disease, HIV
Acinetobacter baumanii (1) [Sputum PCR]Community-acquired Pneumonia
Ascaris lumbricoides (1) [Microscopy]Typhoid Fever
Enterococcus avium (1) [Pus culture]Diabetic Ulcer
Escherichia coli (1) [Urine culture]UTI
HIV (1) [PCR]Sepsis
Leptospira spp. (1) [PCR]Dengue Hemorrhagic Fever I
Moraxella catarrhalis and Influenza B (1) [Sputum culture and sputum PCR]Community-acquired Pneumonia
RSV (1) [Serology]TB Pleuritis
Streptococcus pneumoniae (1) [Sputum PCR]Community-acquired Pneumonia
Unknown (41) [None]HIV (6), Sepsis (6), Community-acquired Pneumonia (9), Cellulitis (2), Cholangitis (2), Lung Abscess, Acute Leukemia, Bacterial Meningitis, Bronchitis, Cholecystitis, Chronic Myelocytic Leukemia, COPD, Diarrhea, Extrapulmonary TB, GEA, Hepatitis B, Pancytopenia, SLE, Typhoid Fever, UTI, Unknown

Discussion

BSI causes a high burden of morbidity and mortality worldwide, particularly in low- and middle-income countries (LMICs). Exact figures for BSI incidence and associated mortality in LMICs are challenging to find due to the lack of bacteriological laboratories and routine surveillance systems [38, 39]. In Indonesia, very few acute febrile patients undergo aerobic blood culture testing since it is not standard practice in the healthcare system, largely due to resource and capacity restrictions [17]. The AFIRE study presents a unique opportunity to improve our understanding of BSIs in the country since aerobic blood cultures were performed on nearly all participants, regardless of clinical suspicion of bacteremia. Microbial growth was observed in 10.3% of all participants, with bacteremia being ultimately confirmed in 6.3% of all participants (Fig 1). These proportions are similar to previous reports, where positivity rates ranged from 10.0–11.4% [17]. The high prevalence of dengue fever in Indonesia often complicates the clinical assessment of acute febrile illness [25], so specimens from all participants in the AFIRE study were retrospectively tested for dengue NS1 antigen to exclude dengue as a cause of illness [19]. Data on co-infections with dengue virus and bacteremia is limited. A literature review of published case reports and studies from January 1943 to March 2016 found 3 studies in Singapore and Taiwan reporting concurrent bacteremia in 0.18–7% of dengue fever cases [40-42]. A concurrent dengue virus and S. Typhi case was also reported from Bandung, Indonesia [43]. In all of these studies, blood was collected for bacterial culture because patients did not improve clinically a few days to a week after dengue fever was diagnosed. Furthermore, in the majority of cases, dengue virus infection was confirmed by serology only (IgM detected or four-fold IgG increase). These reports support our finding that simultaneous infection with bacteria and dengue virus is rare. In our study, bacterial growth observed in 14 participants with positive dengue NS1 antigen tests were considered false positive blood cultures (5 Staphylococcus hominis, 4 Staphylococcus epidermidis, 1 Kocuria rosea, 1 Micrococcus aureus, 1 Staphylococcus arlettae, 1 coagulase-negative Staphylococcus spp., and 1 Staphylococcus waneri). Among dengue-negative participants with any microbial growth, 97.8% had blood cultures performed from two sides of collection. One-sided blood culture lacks sufficient sensitivity for BSI detection [44], and two-sided cultures make it easier to distinguish true bacteremia and contamination [44, 45]. It has been demonstrated that collecting two or more blood culture sets, each comprising two bottles, over twenty-four hours will detect over 94% of bacteremia episodes, compared to a detection rate of only 73% with the first blood culture [44]. In many developing countries, collecting multiple blood culture sets is generally not feasible, but the minimum practice of a single, one-sided blood culture still has value if clinical care teams understand its limitations. Our data suggest that, in situations where a single, one-sided blood culture is performed, the likelihood of missing a case of bacteremia is 39% (35/89) (8.9% (89/1000) vs 5.4% (54/1000) (Fig 1). Indonesian clinicians should consider this reduced sensitivity when acting on culture results. The reliability and interpretation of blood culture results is significantly affected by both contamination rates and the use of antibiotics prior to blood collection. General target rates for culture contamination have been set at 3% [45], and in our study we observed an overall contamination rate of 3.6%. These findings are consistent with previous reports, including a 2010–2013 study at Sardjito Hospital in Yogyakarta that found a contamination rate of 4.1% in children at the pediatric ICU and in pediatric wards [46]. Additional reports from rural Thailand and Taiwan found contamination rates ranging from 4.1–6.1% and 2.6%, respectively [47, 48]. The proportion of participants who were given intravenous antibiotics prior to blood collection in our study was high (40.2%), and this may alter the blood culture results considerably [49, 50]. In Indonesia, antibiotic therapy is often initiated preemptively and without confirmatory testing in an attempt to maximize positive clinical outcomes [51]. This broad use of antibiotics likely masks the true prevalence of bacteremia and may have negative consequences for patients who subsequently appear to have no infection. Among participants with false positives or no growth, 111 had culturable microbes confirmed by other methods (Table 4), 7 of which died (Table 5). 56.8% of these overall participants received antibiotics prior to blood collection. The expansion of molecular methods would significantly help to tackle this problem, as nucleic acid probe and amplification tests have been shown to significantly improve the speed and accuracy of results in blood stream infections even after antibiotic use [52, 53]. White blood cell counts, particularly leukopenia and leukocytosis, have been used to predict blood culture results. However, the accuracy of systemic inflammatory response syndrome (SIRS) criteria [54], Shapiro criteria [55], and the quick Sequential Organ Failure Assessment (qSOFA) score [56] could not be confirmed in our study. This is primarily due to the significant difference in leukocyte profiles between participants with Salmonella spp. versus non-Salmonella spp. infections. Our study suggests, as proposed by Ombelet [57] and Seigel [58] that leukocytosis should not be used as a predictor for positive blood cultures in S. enterica-endemic areas. We found that S. Typhi and S. Paratyphi A infection was the most common community-acquired BSI (Table 1) at 55.4% of cases, which aligns with previous studies conducted in limited-resource environments [46, 47]. The majority of S. Typhi and S. Paratyphi A bacteremia was in pediatrics, which is consistent with a previous report from a blood culture study in Jakarta where the incidence rate of typhoid fever was higher in the 2–15 year age group, with a mean age of onset of 10.2 years [59]. This commonly observed age association may be due to poor hygiene practices or the consumption of foods, particularly street food, outside of the home [60]. Though over half of bacteremia cases were due to S. Typhi and S. Paratyphi A infection, only 21.4% of bacteremia deaths were due to the pathogen. Among these fatal cases, all had significant comorbidities, suggesting that patients with multiple comorbidities would benefit from prioritization of blood culture diagnostics. Despite the high prevalence of S. Typhi and S. Paratyphi A among participants with bacteremia, previous reports have found the overall sensitivity of blood cultures to be only 66% (95% CI 56–75%) when compared to more sensitive tests such as bone marrow cultures [61]. Though bone marrow cultures were not performed as part of our study, further molecular and serological testing as part of the AFIRE study identified an additional 51 cases in the false positive and no growth groups (Table 4), 2 of which were fatal. Most participants with negative blood cultures and false positive results (41.5%) had already received IV antibiotics prior to blood collection, which may have substantially diminished the yield of blood cultures [49, 50]. While blood collection prior to antibiotic administration is ideal, an environment like Indonesia, where preemptive antibiotic use is common, would significantly benefit from supplementing blood culture testing with molecular and serological tests. These tests do have drawbacks, as molecular diagnostics can have poor sensitivity due to the low organism burden in bodily fluids [62], and serological diagnostics require increasing titers in convalescent specimens compared to acute specimens given high background antibody levels in endemic regions [63]. Further research on combining a clinical prediction algorithm with disease‐specific blood cultures for patients with febrile illnesses in typhoid-endemic areas could be a potential route to improve patient outcomes in a community‐based setting while waiting for the wider adoption of molecular and serological testing. Among cases of S. Typhi and S. Paratyphi A bacteremia, the prevalence of antimicrobial resistance to the antibiotic of choice was only 3.9% (Fig 2), which is similar to previous studies in Indonesia [64-66]. In the 2011–2015 period, rates of resistance against most antimicrobials for S. Typhi and S. Paratyphi A were low, indicating that there is a distinct epidemiological dynamic of enteric fever in Indonesia compared to the rest of the world [64, 67]. This could be due to different strains of S. Typhi and S. Paratyphi A which may possess different genes that contribute to resistance [64, 65], though we did not perform genotyping or sequencing as part of our study. In addition to S. Typhi and S. Paratyphi A bacteremia, we identified cases of bacteremia caused by other WHO GLASS and non-GLASS pathogens. E. coli was the second most common cause of BSI, with over half of isolates possessing some form of antimicrobial resistance. Both fatal cases were found to possess third-generation cephalosporin (3GC) and fluoroquinolone resistance. The global incidence of community-acquired BSI due to E. coli is relatively high, with an estimated 50–60 cases per 100,000 population [68-70], and the proportion of 3GC resistance has reached levels >60% in some parts of the world [71, 72]. We found 3GC-resistance rates of 35.7% in our study, which is consistent with the WHO GLASS report of 36.6% (interquartile range [IQR] 17.5–58.3) [37]. The fluoroquinolone-resistance rates of 22% that we observed were high but consistent with previous reports from Indonesia [73, 74]. Bacteremia from S. aureus infection was found in 10.9% cases in our study, and the observed mortality rate of 20% was consistent with a previous report [75]. Both participants who died were diabetic and contracted oxacillin-sensitive infections, suggesting that the cause of death may have been due more to the timing of diagnosis and treatment. It is well-known that diabetics are at high risk for infections with S. aureus [76], so comorbidities should be strongly considered when prioritizing blood culture testing. Two participants with systemic lupus erythematosus (SLE) developed S. aureus BSIs, which has been associated with classic hyper-IgE syndrome [77]. The colonization of S. aureus in the body often increases in patients with SLE and may predispose them to BSI, worsening the SLE itself and leading to a feedback loop with the potential to reinforce autoimmune symptoms [78, 79]. The proportion of MRSA in our study (10%) was lower than the WHO GLASS report (24.9% (IQR 11.4–42.7)) [37], though this is understandable given that our study was not a systematic surveillance of S. aureus infections across the country. Geographic variation of CAI with MRSA has been observed in the Asia-Pacific region, including Taiwan, the Philippines, Vietnam, and Sri Lanka (30–39%); Korea and Japan (15–20%); and Thailand, India, and Hong Kong (3–9%) [80, 81]. Data from Indonesia remains limited, but a recent study has shown that the carriage rate of MRSA in the nose and throat of patients admitted to surgery and internal medical wards at Dr. Soetomo Hospital in Surabaya was 8.1% among 643 patients [82]. Additionally, a report on 259 S. aureus isolates collected from clinical cultures of patients at four tertiary care hospitals in Denpasar, Malang, Padang, and Semarang found that 6.6% and 18.5% were MRSA and PVL-positive methicillin-susceptible S. aureus, respectively [83]. Besides E. coli and S. aureus, we observed the other WHO GLASS pathogens K. pneumonia, S. pneumonia, and Acinetobacter spp. in our study. K. pneumonia was mostly found in patients with UTI and respiratory illnesses. The two fatal cases were most likely associated with the participants’ chronic illnesses (stroke and kidney failure), as none of the isolates were 3GC, fluroquinolone, or co-trimoxazole resistant. Both cases of S. pneumonia bacteremia were found in pediatric participants, and both were fatal. The participant with a penicillin-sensitive infection had myelodysplasia syndrome, and the participant with a ceftriaxone-resistant infection had clinical meningitis. S. pneumonia was also found by molecular methods in 8 participants whose blood cultures were negative, supporting a previous report that successful diagnostic approaches using blood cultures alone are difficult because of reduced sensitivity [84]. Acinetobacter lwoffii was identified in two participants, both having gastro-intestinal symptoms and receiving an initial diagnosis of typhoid fever. Treatment with cefixime resolved the infections. A similar case with fever, abdominal pain, and diarrhea has been reported in a 64 year-old man in Texas, USA [85]. Our study found the most frequent BSI pathogens to be S. Typhi and E. coli, though multidrug-resistant E. coli was the most problematic. The challenges of AMR in Indonesia are similar to those of many other low and middle-income countries in the region and globally [20]. Misuse and overuse of antibiotics in humans, livestock, and aquaculture may be the key drivers of resistance in the country [86]. Despite current policies related to antimicrobial use in Indonesia, frequent and unnecessary prescription of antibiotics by physicians, high rates of self-medication, and over-the-counter access to antibiotics remain common [87]. Since 2016, the Indonesia Ministry of Health has boosted their AMR stewardship program to tackle this growing challenge, directing substantial funding to the national AMR control committee [20]. Further support for AMR prevention and the alignment of national policies with global policies and standards will substantially improve the growing challenge of AMR infections in Indonesia. Our study has several limitations. First, the blood specimens analyzed as part of this study were collected only from a limited number of extremely ill patients admitted to tertiary hospitals. Blood culture positivity rates, AMR patterns, and clinical outcomes may not be generalizable to the Indonesian population at-large, though better understanding this critically ill population will hopefully lead to a reduction in mortality from BSIs. Second, only aerobic blood cultures were performed, which may have resulted in missed BSIs caused by anaerobic bacterial. The generally low yield of anaerobic bacteria combined with increasing costs and volumes of blood drawn [13, 88, 89] make anaerobic cultures impractical for many hospitals in Indonesia. In the future, rationally targeting the use of anaerobic culture bottles based on careful clinical assessment may result in substantial savings and facilitate the broader adoption of the diagnostic in the country [90]. Lastly, AMR susceptibility testing in this study was performed and reported according to general practice in Indonesia, as our study was not initially designed as an AMR study. Consequently, our data has substantial gaps and missing information. A standardized approach and electronic results reporting system in Indonesia would significantly improve the accuracy and utility of AMR susceptibility testing.

Conclusion

We presented aerobic blood culture findings from a multi-centre study of patients with acute febrile illness admitted to eight major hospitals across Indonesia. Our universal use of aerobic blood cultures is unique in Indonesia, the results of which help clarify the epidemiology and burden of BSI, rates of contamination among CAI, and common AMR patterns in Indonesia. Bacteremia was observed in 8.9% participants, with the most frequent pathogens being S. Typhi and S. Paratyphi A, E. coli, and S. aureus. Two S. Paratyphi A cases had evidence of AMR, and several E. coli cases were multidrug resistant (42.9%) or monoresistant (14.3%). Culture contamination was observed in 3.6% cases. Our data suggest that blood cultures should be included as a routine diagnostic test, and pre-screening patients for the most common viral infections, such as dengue, influenza and chikungunya viruses, would conserve scarce resources without negatively impacting patient benefit. The routine practice of AMR susceptibility testing on positive blood cultures in Indonesia is encouraging and should be continued to inform clinical decisions on patient treatment in real-time. The country could benefit from clear guidance at the national level, particularly regarding the timing of blood collection prior to antibiotic administration, the prioritization of patients with comorbidities, blood collection practices to reduce environmental contamination, and the supplementation of blood cultures with molecular assays to combat false-negative results. Additionally, Indonesia could greatly benefit from a nationwide program for the systematic collection and dissemination of blood culture and AMR results. (XLSX) Click here for additional data file. 30 May 2022
PONE-D-22-07517
The Characteristics of Bacteremia among Patients with Acute Febrile Illness Requiring Hospitalization in Indonesia
PLOS ONE Dear Dr. Kosasih, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jul 14 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Dwij Raj Bhatta, PhD Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments (if provided): Submitted manuscript on very important study requires corrections in each section as pointed out by reviewers! Specially adress all the comments made by reviewers& answer important questions raised! [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This compilation of data from different centers over many years is commendable. This highlights the issues faced in diagnostic microbiology in developing countries. It is an interesting paper with important observations and discussions. Some spellings need review and correction. Recommend to submit after corrections. Reviewer #2: The Characteristics of Bacteremia among Patients with Acute Febrile Illness Requiring Hospitalization in Indonesia. Evaluation. This report addresses an important subject in Bacteriemia and Acute Febrile illness; i.e., the worrying trend of antimicrobial resistance in bacterial pathogens (Salmonella and Non Salmonella spp) . It reports the frequency and distribution of bacterial pathogens in blood culture and its susceptibility pattern isolated from various specimens from a seven medical center in Indonesia, from which similar reports are scarce. Though it is better attempt by Soedarmono et al., to know information on bacteremia and other causative agent of Acute Febrile illeness in Indonesia. Comments 1.Give rationale of the study? Why is NS1 antigen screening only performed? What about other viral agents related AFI? 2.Why you performed Blood culture 0f 1459 Cases? You have mentioned 1464 were enrolled? What about 5?? 3.At the end of introduction, please give some update of Acute Febrile illness and their epidemiology in Indonesia. 4.Which are the hospitals included in the study, please mentions the name of hospitals. 5.How do you calculate sample size? Is it sufficient to draw conclusion regarding bacteremia (causative bacterial pathogens) in Indonesia? 6.What is your inclusion and exclusion criteria? Please mention Clearly. 7.Please give the ethical approval committee name and approval number and date. 8.How do assure the Quality controls and quality check of your results, either BD 135 Phoenix (Becton Dickinson) or VITEK 2 (bioMérieux, Inc., Durham, North Carolina), System? 9.What is the volume of blood sample collected and used in culture from children and adults? 10.It is better to give numerator value after percentage values. 11.Please give the full name of bacteria initially such as Staphylococcus aureus and then short form S. aureus and other bacteria throughout the manuscript. 12.Please mention the more information on infections with dengue virus and bacteremia in Indonesia. 13.Please corelate conclusion with your findings. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Dr Shishir Gokhale Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
14 Jul 2022 Dear Dwij Raj Bhatta, PhD Academic Editor PLOS ONE Thank you very much for the constructive comments and suggestions provided by the reviewers. We have carefully revised the manuscript following the suggestions. Please see the response to each comment/suggestion below. Reviewer #1: This compilation of data from different centers over many years is commendable. This highlights the issues faced in diagnostic microbiology in developing countries. It is an interesting paper with important observations and discussions. Some spellings need review and correction. Recommend to submit after corrections. Response: Thank you very much for your comments, we really appreciate it. We have corrected the spelling errors. Reviewer #2: The Characteristics of Bacteremia among Patients with Acute Febrile Illness Requiring Hospitalization in Indonesia. Evaluation. This report addresses an important subject in Bacteriemia and Acute Febrile illness; i.e., the worrying trend of antimicrobial resistance in bacterial pathogens (Salmonella and Non Salmonella spp) . It reports the frequency and distribution of bacterial pathogens in blood culture and its susceptibility pattern isolated from various specimens from a seven medical center in Indonesia, from which similar reports are scarce. Though it is better attempt by Soedarmono et al., to know information on bacteremia and other causative agent of Acute Febrile illeness in Indonesia. Response: Thank you very much for your comments, we really appreciate it. Comments 1.Give rationale of the study? Why is NS1 antigen screening only performed? What about other viral agents related AFI? Response: We have added more information regarding this issue in the Methods. Lines 135-146 now read: During the baseline visit, blood was collected for cultures, clinically relevant rapid diagnostic tests when available, and dengue virus rapid diagnostic tests. Dengue virus infection remains a significant burden across Indonesia [28,29], with disease incidence increasing in recent years [30]. Though other viral agents are present in Indonesia, none are as prevalent as dengue virus [24,31], and most are challenging to diagnose due to limitations with available rapid diagnostic tests [32,33]. Given the widespread prevalence of dengue virus infection, and the very high specificity (almost 100%) and good sensitivity (70-87%) of NS1 antigen rapid diagnostic tests [34], we employed universal dengue virus screening to rapidly resolve the unknown etiologies of study participants. Participants with negative NS1 antigen tests were further considered for BSIs through blood culture tests and other etiologies, as determined through advanced testing at the INA-RESPOND reference laboratory. 2.Why you performed Blood culture 0f 1459 Cases? You have mentioned 1464 were enrolled? What about 5?? Response: We only performed blood culture for 1459 patients, as the remaining 5 subjects did not have enough blood for blood culture test. Lines 207-210 now read: The remaining 5 participants had insufficient blood specimens for following reasons: 1 adult was in a severe condition (decreased of consciousness), 2 participants (1 child and 1 adult) self-discharged against medical advice, and the guardians of 2 children refused to allow more blood to be drawn. 3.At the end of introduction, please give some update of Acute Febrile illness and their epidemiology in Indonesia. Response: Thank you very much for the suggestion. We have added some update of acute febrile illness and their epidemiology in Indonesia. Lines 97-111 now read: The epidemiology of pathogens associated with fever in Indonesia is not well understood, as public health surveillance data is limited and only a few local studies have been conducted [19,21-26]. Among published studies, dengue virus, chikungunya virus, influenza virus, Salmonella Typhi, Rickettsia spp., and Leptospira spp. are consistently the most common causes of acute febrile illness hospitalizations. A study in Papua from November 1997 to February 2000 enrolled 226 hospitalized patients that were negative for malaria, the majority of whom were determined to have typhoid fever (18%), leptospirosis (12%), rickettsioses (8%), and dengue fever (7%) [23]. An observational fever study in Bandung identified dengue virus in 12.4% of fever episodes, followed by S. Typhi (7.4%), and chikungunya virus (7.1%) [24,26,27]. A 2005-2006 study in Semarang found rickettsioses and leptospirosis in 7% and 10%, respectively, of 137 acute undifferentiated fever cases [21]. The parent study of the research presented here found the most prevalent pathogens among participants at eight hospitals in 7 major cities in Indonesia to be dengue virus (27-52%), Rickettsia spp. (2-12%), S. Typhi (0.9-13%), influenza virus (2-6%), Leptospira spp. (0-5%), and chikungunya virus (0-4%) [19]. 4.Which are the hospitals included in the study, please mentions the name of hospitals. Response: We have included the name of hospitals in the Methods. Lines 121-127 now read: A prospective observational study enrolling febrile patients who required hospitalization was conducted by the Indonesia Research Partnership on Infectious Disease (INA-RESPOND) from July 2013 to June 2016 at eight major hospitals in seven provincial capitals in Indonesia: Dr. Cipto Mangunkusumo Hospital in Jakarta, Sulianti Saroso Infectious Disease Hospital in Jakarta, Dr. Wahidin Sudirohusodo Hospital in Makassar, Dr. Sardjito Hospital in Yogyakarta, Dr. Hasan Sadikin Hospital in Bandung, Sanglah General Hospital in Denpasar, Dr. Soetomo Hospital in Surabaya, and Dr. Kariadi Hospital, in Semarang. 5.How do you calculate sample size? Is it sufficient to draw conclusion regarding bacteremia (causative bacterial pathogens) in Indonesia? Response: As this study was an observational study to find etiologies of acute febrile illness during a certain period of time (2013-2016), we did not specifically calculate the sample size for drawing the conclusion regarding bacteremia in Indonesia. Since we performed the analysis of blood culture results from almost all participants (>99% participants, approximately 100 adults and 100 children from each hospital), though cannot be generalizable to the Indonesian population at-large, we expected that the data will provide better understanding of the bacteremia in hospitalized population with fever and hopefully will lead to a reduction in mortality from BSIs. 6.What is your inclusion and exclusion criteria? Please mention Clearly. Response: We have added the inclusion and exclusion criteria. Lines 128-131 now read: Briefly, inclusion criteria consisted of axillary body temperature �  38˚C, �  1 year of age, and hospitalization within the past 24 hours. Patients were excluded from the study if they had subjective fever for �  14 days or were hospitalized in the last 3 months. 7.Please give the ethical approval committee name and approval number and date. Response: The name of the ethical approval committee and approval number had already provided under the “Ethical Clearance” (lines 197-203); and we have added the date. Ethical approvals for the AFIRE study were granted by the Institutional Review Boards of the National Institute of Health Research and Development (NIHRD), Indonesia Ministry of Health (KE.01.05/EC/407/2012) dated 23 May 2012, the Faculty of Medicine at the University of Indonesia and RSUPN Dr. Cipto Mangunkusumo Hospital (451/PT02.FK/ETIK/2012) dated 23 July 2012, and RSUD Dr. Soetomo Hospital (192/Panke.KKE/VIII/2012) dated 13 August 2012. 8.How do assure the Quality controls and quality check of your results, either BD 135 Phoenix (Becton Dickinson) or VITEK 2 (bioMérieux, Inc., Durham, North Carolina), System? Response: Blood culture tests were performed at the hospital's accredited clinical laboratory, which provides patient diagnostic services. All instruments and standards were calibrated appropriately according to manufacturer guidelines. Every site’s laboratory performed quality control (QC) to ensure proper performance and sent the QC report to protocol team to be reviewed. All tests were run alongside appropriate positive and negative control to ensure the integrity and accuracy of the results. For example, QC for VITEK 2 system; each new lot number of ID cards is tested with stock culture organisms. Susceptibility cards are tested weekly against stock culture organisms. The QC organisms uses as follows: Weekly: AST-GP 67 cards Enterococcus faecalis ATCC 29212 AST-GN 66 cards E. coli ATCC 25922 non fermenter PSA ATCC 27853 fermenter E. coli ATCC 35218 non fermenter ID-NH cards Elkenella corrodens ATCC BAA-1152 New Lots: ID-GP cards Enterococcus casseliflavis ATCC 700327 ID-GN cards Enterobacter hormechei (E.cloacae) ATCC 700323 Lines 163-171 now read: Blood cultures were performed and analyzed at the hospitals’ nationally accredited clinical laboratories by trained, certified staff. All instruments and standards were calibrated appropriately according to manufacturer guidelines, and all tests were run alongside appropriate positive and negative control to ensure the integrity and accuracy of the results. Organism identification was considered acceptable when the confidence level in the automated growth identification system was ≥95% probability [34]. Quality control tests were performed weekly at all site laboratories, and each new lot of ID cards was tested using validated stocks of culture organisms. 9.What is the volume of blood sample collected and used in culture from children and adults? Response: This is already stated in the text. Blood volumes of approximately 5-8 mL for adults and 1-3 mL for children were collected from each arm, whenever possible, directly into separate aerobic blood culture bottles (lines 150-152). 10.It is better to give numerator value after percentage values. Response: We have changed the presentation throughout the manuscript. 11.Please give the full name of bacteria initially such as Staphylococcus aureus and then short form S. aureus and other bacteria throughout the manuscript. Response: We have followed your suggestion. 12.Please mention the more information on infections with dengue virus and bacteremia in Indonesia. Response: We found no dengue virus and bacteremia co-infection in our study, as mentioned in the Discussion. We have added more informations about dengue virus and bacteremia. Lines 355-368 now read: Data on co-infections with dengue virus and bacteremia is limited. A literature review of published case reports and studies from January 1943 to March 2016 found 3 studies in Singapore and Taiwan reporting concurrent bacteremia in 0.18-7% of dengue fever cases [40-42]. A concurrent dengue virus and S. Typhi case was also reported from Bandung, Indonesia [43]. In all of these studies, blood was collected for bacterial culture because patients did not improve clinically a few days to a week after dengue fever was diagnosed. Furthermore, in the majority of cases, dengue virus infection was confirmed by serology only (IgM detected or four-fold IgG increase). These reports support our finding that simultaneous infection with bacteria and dengue virus is rare. In our study, bacterial growth observed in 14 participants with positive dengue NS1 antigen tests were considered false positive blood cultures (5 Staphylococcus hominis, 4 Staphylococcus epidermidis, 1 Kocuria rosea, 1 Micrococcus aureus, 1 Staphylococcus arlettae, 1 coagulase-negative Staphylococcus spp., and 1 Staphylococcus waneri). 13.Please corelate conclusion with your findings. Response: Thank you very much, we have correlated our conclusion with our findings. Lines 522-541 now read: We presented aerobic blood culture findings from a multi-centre study of patients with acute febrile illness admitted to eight major hospitals across Indonesia. Our universal use of aerobic blood cultures is unique in Indonesia, the results of which help clarify the epidemiology and burden of BSI, rates of contamination among CAI, and common AMR patterns in Indonesia. Bacteremia was observed in 8.9% participants, with the most frequent pathogens being Salmonella spp., E. coli, and S. aureus. Two Salmonella spp. cases had evidence of AMR, and several E. coli cases were multidrug resistant (42.9%) or monoresistant (14.3%). Culture contamination was observed in 3.6% cases. Our data suggest that blood cultures should be included as a routine diagnostic test, and pre-screening patients for the most common viral infections, such as dengue, influenza and chikungunya viruses, would conserve scarce resources without negatively impacting patient benefit. The routine practice of AMR susceptibility testing on positive blood cultures in Indonesia is encouraging and should be continued to inform clinical decisions on patient treatment in real-time. The country could benefit from clear guidance at the national level, particularly regarding the timing of blood collection prior to antibiotic administration, the prioritization of patients with comorbidities, blood collection practices to reduce environmental contamination, and the supplementation of blood cultures with molecular assays to combat false-negative results. Additionally, Indonesia could greatly benefit from a nationwide program for the systematic collection and dissemination of blood culture and AMR results. Submitted filename: Response to Reviewer - Blood Culture.docx Click here for additional data file. 21 Jul 2022
PONE-D-22-07517R1
The Characteristics of Bacteremia among Patients with Acute Febrile Illness Requiring Hospitalization in Indonesia
PLOS ONE Dear Dr. Kosasih, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 04 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Dwij Raj Bhatta, PhD Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: manuscript requires few corrections in the section abstract method result discussion and conclusion, minor revision required . Please go through the comments made in manuscript. Serovar names of salmonella isolates obtained during present study be mentioned whereever required in the manuscript [Note: HTML markup is below. Please do not edit.] [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
Submitted filename: PONE-D-22-07517_R2.pdf Click here for additional data file. 8 Aug 2022 Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Response: We have reviewed our reference list to ensure that it is complete and correct. As per today (27 July 2022), no cited papers have been retracted. Therefore, no change of the reference list has been made. Additional Editor Comments: manuscript requires few corrections in the section abstract method result discussion and conclusion, minor revision required . Please go through the comments made in manuscript. Serovar names of salmonella isolates obtained during present study be mentioned whereever required in the manuscript Response: Thank you very much. We have gone through the comments made in manuscript and revised the manuscript accordingly. When required/appropriate, we have reported names of salmonella isolates obtained during the present study throughout the manuscript (41 cases of S. Typhi and 10 cases of S. Paratyphi A). However, we have not mentioned the serovar names when we refer the subjects with Salmonella spp. and non-Salmonella spp. as groups. Abstract (lines 55-61 now read): Bacteremia was observed in 8.9% (92) participants, with the most frequent pathogens being Salmonella enterica serovar Typhi (41) and Paratyphi A (10), Escherichia coli (14), and Staphylococcus aureus (10). Two S. Paratyphi A cases had evidence of AMR, and several E. coli cases were multidrug resistant (42.9%, 6/14) or monoresistant (14.3%, 2/14). Culture contamination was observed in 3.6% (37) cases. Molecular and serological assays identified etiological agent in participants having negative cultures, with 23.1% to 90% of cases being missed by blood cultures. Other changes have been made with “track changes” in the manuscript. Submitted filename: Response to Editor.docx Click here for additional data file. 9 Aug 2022 The Characteristics of Bacteremia among Patients with Acute Febrile Illness Requiring Hospitalization in Indonesia PONE-D-22-07517R2 Dear Dr. Kosasih, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Dwij Raj Bhatta, PhD Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: 29 Aug 2022 PONE-D-22-07517R2 The Characteristics of Bacteremia among Patients with Acute Febrile Illness Requiring Hospitalization in Indonesia Dear Dr. Kosasih: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Professor Dwij Raj Bhatta Academic Editor PLOS ONE
  82 in total

1.  Comparative evaluation of the BD Phoenix and VITEK 2 automated instruments for identification of isolates of the Burkholderia cepacia complex.

Authors:  Sylvain Brisse; Stefania Stefani; Jan Verhoef; Alex Van Belkum; Peter Vandamme; Wil Goessens
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

Review 2.  Update on blood cultures: how to obtain, process, report, and interpret.

Authors:  T J Kirn; M P Weinstein
Journal:  Clin Microbiol Infect       Date:  2013-03-13       Impact factor: 8.067

3.  Predicting bacteremia in hospitalized patients. A prospectively validated model.

Authors:  D W Bates; E F Cook; L Goldman; T H Lee
Journal:  Ann Intern Med       Date:  1990-10-01       Impact factor: 25.391

Review 4.  Advances in Rapid Molecular Blood Culture Diagnostics: Healthcare Impact, Laboratory Implications, and Multiplex Technologies.

Authors:  Rosemary C She; Jeffrey M Bender
Journal:  J Appl Lab Med       Date:  2018-11-21

Review 5.  Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options.

Authors:  Gisele Peirano; Johann D D Pitout
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

6.  Dengue viruses circulating in Indonesia: A systematic review and phylogenetic analysis of data from five decades.

Authors:  Harapan Harapan; Alice Michie; Benediktus Yohan; Pei-Yun Shu; Mudatsir Mudatsir; R Tedjo Sasmono; Allison Imrie
Journal:  Rev Med Virol       Date:  2019-05-16       Impact factor: 6.989

7.  A prospective study of bloodstream infections as cause of fever in Malawi: clinical predictors and implications for management.

Authors:  Remco P H Peters; Ed E Zijlstra; Maarten J Schijffelen; Amanda L Walsh; George Joaki; John J Kumwenda; James G Kublin; Malcolm E Molyneux; David K Lewis
Journal:  Trop Med Int Health       Date:  2004-08       Impact factor: 2.622

8.  Antimicrobial Resistance of Salmonella enterica Serovars Typhi and Paratyphi Isolates from a General Hospital in Karawaci, Tangerang, Indonesia: A Five-Year Review.

Authors:  Nata Pratama Hardjo Lugito
Journal:  Int J Microbiol       Date:  2017-04-06

9.  Murine typhus and leptospirosis as causes of acute undifferentiated fever, Indonesia.

Authors:  M Hussein Gasem; Jiri F P Wagenaar; Marga G A Goris; Mateus S Adi; Bambang B Isbandrio; Rudy A Hartskeerl; Jean Marc Rolain; Didier Raoult; Eric C M van Gorp
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

Review 10.  Modern Blood Culture: Management Decisions and Method Options.

Authors:  Mark D Gonzalez; Timothy Chao; Matthew A Pettengill
Journal:  Clin Lab Med       Date:  2020-09-19       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.